Michael Carleton

Title: Michael Carleton: Innovator in Cancer Treatment

Introduction

Michael Carleton is a notable inventor based in Princeton, NJ (US). He has made significant contributions to the field of cancer treatment through his innovative approaches and patented technologies. With a total of 2 patents, Carleton's work focuses on combining therapies to enhance the effectiveness of cancer treatments.

Latest Patents

One of Carleton's latest patents is titled "Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer." This invention provides methods for the clinical treatment of tumors, particularly advanced solid tumors, in patients with specific levels of serum IL-8. The therapy utilizes an anti-IL-8 antibody in conjunction with an anti-PD-1 antibody to improve patient outcomes. Another significant patent is "Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer." This invention outlines methods for treating pancreatic cancer using specific dosage regimes of antibodies that target colony stimulating factor 1 receptor (CSF1R) and programmed cell death 1 (PD-1).

Career Highlights

Throughout his career, Michael Carleton has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. His experience in these organizations has contributed to his expertise in developing innovative cancer therapies.

Collaborations

Carleton has collaborated with several professionals in his field, including David Feltquate and Olivier De Henau. These partnerships have facilitated the advancement of his research and the successful development of his patented technologies.

Conclusion

Michael Carleton's contributions to cancer treatment through his innovative patents demonstrate his commitment to improving patient care. His work continues to influence the field of oncology and offers hope for more effective cancer therapies in the future.